Dysport vs. Xeomin: Spread, Onset, and the “Naked Toxin” Question (2026 Guide)

Dysport and Xeomin sit at opposite ends of the type-A neurotoxin family in two important ways. Dysport is a slightly broader-spreading product known for fast onset and pricing efficiency on large treatment areas. Xeomin is the “naked toxin” — a 150 kDa formulation with no accessory complexing proteins — that diffuses tightly and is sometimes chosen specifically because of its minimalist excipient profile.

Both are FDA-approved type-A botulinum toxins. Both quiet the same muscles. Both last roughly 3–4 months. But the spread profile and what is in (or not in) the vial are meaningfully different, and those differences can absolutely affect which one is the better fit for your face. This guide walks through every meaningful difference based on the current FDA labels, the head-to-head literature on Dysport, Botox, and Xeomin, and the per-treatment pricing you will actually see at a U.S. clinic in 2026.

What Dysport and Xeomin Actually Are

Both are purified type A botulinum toxins. Both work by temporarily blocking acetylcholine release at the neuromuscular junction, relaxing targeted facial muscles. The clinical endpoint is the same; what surrounds the active 150 kDa toxin is very different.

• Dysport (abobotulinumtoxinA) — manufactured by Galderma, FDA-approved cosmetically for glabellar lines in April 2009. Dysport is a complex of roughly 500–900 kDa, with a higher proportion of free 150 kDa active toxin than Botox. It is formulated with human serum albumin and lactose.
• Xeomin (incobotulinumtoxinA) — manufactured by Merz Aesthetics, FDA-approved cosmetically for glabellar lines in 2011. Xeomin is the bare 150 kDa toxin with no accessory proteins (“naked toxin”). It is formulated without human serum albumin in the active component. That clean profile is its signature feature.

This is the core distinction between these two products: Dysport surrounds its active toxin with a larger, looser complex that diffuses outward; Xeomin removes the accessory protein scaffolding entirely and behaves like a precise, predictable point injection.

Onset: When Will You See Results?

This is one of the largest practical differences between the two products.

• Dysport onset: Most patients see softening at 2–3 days, with peak effect around 10–14 days. Dysport is widely cited as one of the fastest-acting cosmetic toxins on the U.S. market.
• Xeomin onset: Most patients see softening at 5–7 days, with peak effect around 14 days. Xeomin is on the slower-onset end of the type-A toxin family.

For a wedding, an event, or any high-stakes appearance 8–10 days out, the onset gap matters. Dysport can give you noticeable softening within 72 hours; Xeomin typically takes the better part of a week. For routine maintenance where the calendar is open, the difference is academic.

Duration: How Long Will Results Last?

Essentially the same.

• Dysport: Typical glabellar duration is 3–4 months. The FDA label notes effects “may last up to 4 months” and re-treatment no more often than every 3 months.
• Xeomin: Typical glabellar duration is also 3–4 months, in line with Botox and Dysport.

Head-to-head studies — including the well-known Sattler et al. paper directly comparing Xeomin, Botox, and Dysport — have not shown a consistent, clinically meaningful duration advantage for any of these three products. Real-world duration is driven much more by your metabolism, dose adequacy, treatment area, and injection technique than by the brand on the vial. If duration is your single top priority, the longer-acting option to discuss with your injector is Daxxify, which is studied at six months median duration.

Dosing and Unit Conversion

The dosing math is where Xeomin earns part of its reputation for simplicity.

Per the FDA labels:

• Dysport for glabellar lines: 50 units total, divided across 5 injection sites (10 units each). Roughly 2.5–3 units of Dysport equal 1 unit of Botox.
• Xeomin for glabellar lines: 20 units total, divided across 5 injection sites (4 units each). The dosing ratio against Botox is approximately 1:1.

So a typical Dysport patient and a typical Xeomin patient leaving with the same clinical result will have received 50 units versus 20 units. Per-unit price comparisons between these two products are essentially meaningless; the only meaningful comparison is total per-treatment cost. The FDA labels explicitly warn that units are not interchangeable across brands, and any competent injector recalculates from scratch when switching you between them.

Diffusion and Precision

This is the single most important practical difference between Dysport and Xeomin.

Dysport tends to diffuse — spread outward from the injection point — slightly more than its peers. That is well-suited to broad, flat targets:

• Forehead, where you want even softening across a wide muscle with fewer injection points
• Patients who prefer fewer needle pricks per session
• Treatment plans where minor over-spread is helpful rather than risky

Xeomin diffuses tightly, similar to Botox. The bare 150 kDa molecule lacks the accessory complex that helps a toxin migrate through tissue, which is part of why it stays close to where it is placed. That makes Xeomin well-suited to:

• Crow’s feet, where you do not want toxin drifting toward muscles that move your smile
• Lip flips and small perioral targets
• Bunny lines, chin dimpling, and other focal areas where every millimeter matters

A skilled injector can use either product anywhere on the upper face by adjusting dilution and volume per site, but matching the diffusion profile to the anatomy is one of the things your provider should be weighing during your consultation.

Cost: What You Will Actually Pay in 2026

Both products land in the value tier below Botox, but the unit math gets there differently.

• Dysport: roughly $4–$7 per unit. A standard glabellar treatment of 50 units lands around $250–$350.
• Xeomin: roughly $10–$15 per unit. A standard glabellar treatment of 20 units lands around $200–$300.

For glabellar-only patients, Xeomin and Dysport often come in within a similar window per treatment. Xeomin’s per-unit price is higher but it requires fewer units, so the totals land close. For larger-area patients — adding forehead, crow’s feet, or off-label areas — Dysport’s per-unit pricing efficiency tends to pull ahead.

Be careful comparing clinics that quote “per area” instead of “per unit” — per-area pricing can hide undertreatment.

Side Effects and Safety

Both products carry essentially identical short-term side effect profiles, because the mechanism of action is identical. In FDA-controlled trials, the most common adverse events for both were:

• Headache (3–11%)
• Injection-site reactions — bruising, redness, mild swelling (1–5%)
• Eyelid drooping (ptosis), typically less than 1% in trained hands
• Asymmetric brow position, usually correctable with a small touch-up at the two-week mark

Both products carry the FDA boxed warning regarding the theoretical possibility of distant toxin spread; at cosmetic facial doses, this has not been a clinically meaningful concern across millions of treatments.

One specific point worth knowing about Xeomin: because the product contains no accessory complexing proteins, it has been theorized to carry the lowest risk of neutralizing antibody formation across the type-A toxin family. Neutralizing antibodies that reduce a toxin’s effectiveness are rare with any cosmetic neurotoxin in standard dosing — but for patients with a known history of resistance, or those concerned about long-term repeat dosing, the “naked toxin” angle is real. Dysport contains human serum albumin and lactose; patients who specifically want to avoid albumin-containing products for religious, vegan, or other personal reasons may prefer the Xeomin profile.

Who Is the Ideal Candidate for Each?

Dysport may be the better fit if:

• You want visible softening as quickly as possible (often 2–3 days)
• You are treating broad areas like the forehead
• You like the idea of fewer, more widely spaced injection points
• You are a larger-area patient where per-unit pricing efficiency matters

Xeomin may be the better fit if:

• You are treating focal, precision-sensitive areas — crow’s feet, lip flips, bunny lines, chin
• You specifically want to avoid accessory complexing proteins or human serum albumin
• You have concerns about antibody formation from long-term repeat dosing
• You are comfortable waiting 5–7 days to see results in exchange for a tightly localized effect

Can You Switch Between Dysport and Xeomin?

Yes. There is no medical reason you cannot alternate between these products from one treatment to the next. A few practical notes:

• Always tell your new injector exactly which product you previously had, the dose, and roughly when. The unit counts (50 vs. 20) are not interchangeable.
• You cannot stack the two in the same treatment area in the same session.
• Switching products does not require any wash-out period — both work on the same neurotransmitter pathway.
• Patients switching from Dysport to Xeomin often notice a delayed onset (5–7 days vs. 2–3 days) the first time around. This is the product behaving normally, not undertreatment.